RT Journal Article
SR Electronic
T1 Improvement in Delivery of Ischemic Stroke Treatments but Stagnation of Clinical Outcomes in Young Adults in South Korea
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.17.23288712
DO 10.1101/2023.04.17.23288712
A1 Kim, Jonguk
A1 Kim, Jun Yup
A1 Kang, Jihoon
A1 Kim, Beom Joon
A1 Han, Moon-Ku
A1 Lee, Jeong-Yoon
A1 Park, Tai Hwan
A1 Lee, Ji Sung
A1 Lee, Keon-Joo
A1 Kim, Joon-Tae
A1 Choi, Kang-Ho
A1 Park, Jong-Moo
A1 Kang, Kyusik
A1 Lee, Soo Joo
A1 Kim, Jae Guk
A1 Cha, Jae-Kwan
A1 Kim, Dae-Hyun
A1 Lee, Kyungbok
A1 Lee, Jun
A1 Hong, Keun-Sik
A1 Cho, Yong-Jin
A1 Park, Hong-Kyun
A1 Lee, Byung-Chul
A1 Yu, Kyung-Ho
A1 Oh, Mi-Sun
A1 Kim, Dong-Eog
A1 Ryu, Wi-Sun
A1 Choi, Jay Chol
A1 Kwon, Jee-Hyun
A1 Kim, Wook-Joo
A1 Shin, Dong-Ick
A1 Yum, Kyu Sun
A1 Sohn, Sung Il
A1 Hong, Jeong-ho
A1 Lee, Sang-Hwa
A1 Lee, Juneyoung
A1 Gorelick, Philip B.
A1 Bae, Hee-Joon
YR 2023
UL http://medrxiv.org/content/early/2023/07/28/2023.04.17.23288712.abstract
AB Background There is limited information on the delivery of acute stroke therapies and secondary preventive measures and clinical outcomes over time in young adults with acute ischemic stroke (AIS). This study investigated whether advances in these treatments improved outcomes in this population.Methods Using a prospective multicenter stroke registry in Korea, young adults (aged 18–50 years) with AIS hospitalized between 2008 and 2019 were identified. The observation period was divided into four epochs: 2008–2010, 2011–2013, 2014–2016, and 2017–2019. Secular trends for patient characteristics, treatments, and outcomes were analyzed.Results A total of 7,050 eligible patients (mean age 43.1; men 71.9%) were registered. The mean age decreased from 43.6 to 42.9 years (Ptrend=0.01). Current smoking decreased, whereas obesity increased. Other risk factors remained unchanged. Intravenous thrombolysis and mechanical thrombectomy rates increased over time from 2008–2010 to 2017–2019 (9.5% to 13.8% and 3.2% to 9.2%, respectively; Ptrend’s<0.01). Door-to-needle time improved (Ptrend<.001), but onset-to-door and door-to-puncture time remained constant. Secondary prevention including the administration of dual antiplatelets for noncardioembolic minor stroke (26.7% to 47.0%), direct oral anticoagulants for atrial fibrillation (0.0% to 56.2%), and statins for large artery atherosclerosis (76.1% to 95.3%) increased (Ptrend’s<0.01). Outcome data were available from 2011. One-year mortality (2.5% in 2011–2013 and 2.3% in 2017–2019) and 3-month modified Rankin scale scores 0–1 (68.3% to 69.1%) and 0–2 (87.6% to 86.2%) remained unchanged. The one-year stroke recurrence rate increased (4.1% to 5.5%, Ptrend=0.04), altough the differnce was not significant after adjusting for sex and age.Conclusion Improvements in the delivery of acute stroke treatments did not necessarily lead to better outcomes in young adults with AIS over the past decade, indicating a need for further progress.Competing Interest StatementH-J Bae reports grants from Astrazeneca, Bayer Korea, Bristol Myers Squibb Korea, Dong-A ST, Jeil Pharmaceutical Co., Ltd., Samjin Pharm, Takeda Pharmaceuticals Korea Co., Ltd., and Yuhan Corporation, roles as a principal investigator or co-investigator of clinical trials sponsored by Bayer, Bristol Myers Squibb, GNT Pharma, Korean Drug Co., Ltd., Shinpoong Pharm. Co., Ltd., and person fees from Amgen Korea, Bayer, Daiichi Sankyo, JW Pharmaceutical, Hanmi Pharmaceutical Co., Ltd., Otsuka Korea, SK chemicals, and Viatris Korea, outside the submitted work.Funding StatementThis study was supported in part by the Korea Centers for Disease Control and Prevention (no. 2020ER620200f).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRBs of all participating centers (including Seoul National University Bundang Hospital) waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this study may be made available upon request to the corresponding author.